| First Author | Lisi-Vega LE | Year | 2025 |
| Journal | Cell Rep | Volume | 44 |
| Issue | 1 | Pages | 115151 |
| PubMed ID | 39932190 | Mgi Jnum | J:363247 |
| Mgi Id | MGI:7869176 | Doi | 10.1016/j.celrep.2024.115151 |
| Citation | Lisi-Vega LE, et al. (2025) Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia. Cell Rep 44(1):115151 |
| abstractText | In acute myeloid leukemia (AML), malignant cells surviving chemotherapy rely on high mRNA translation and their microenvironmental metabolic support to drive relapse. However, the role of translational reprogramming in the niche is unclear. Here, we found that relapsing AML cells increase translation in their bone marrow (BM) niches, where BM mesenchymal stromal cells (BMSCs) become a source of eIF4A-cap-dependent translation machinery that is transferred to AML cells via extracellular vesicles (EVs) to meet their translational demands. In two independent models of highly chemo-resistant AML driven by MLL-AF9 or FLT3-ITD (internal tandem duplication) and nucleophosmin (NPMc) mutations, protein synthesis levels increase in refractory AML dependent on nestin+ BMSCs. Inhibiting cap-dependent translation in BMSCs abolishes their chemoprotective ability, while EVs from BMSCs carrying eIF4A boost AML cell translation and survival. Consequently, eIF4A inhibition synergizes with conventional chemotherapy. Together, these results suggest that AML cells rely on BMSCs to maintain an oncogenic translational program required for relapse. |
